Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension follow-up of etranacogene dezaparvovec gene therapy in adults with haemophilia B
NL-OMON60354Phase 2Completed
- Sponsor
- CSL Behring
- Start
- Jan 2021
- Modality
- Gene Therapies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of etranacogene dezaparvovec in hemophilia B (HB), sponsored by CSL Behring. Primary endpoints: Long-term safety after dosing of CSL220, Adverse events related to prior CSL220 administration and 4 more. Started Jan 2021; status: completed.
02
Drugs
etranacogene dezaparvovec
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on NL-OMON60354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60354.